So, guess what? Orthocell just released the final results from their study comparing OrthoATI to surgery for treating severe, chronic, treatment-resistant tennis elbow. OrthoATI is a fancy cell therapy made from tendon-derived cells to fix those pesky chronic tendon injuries. And you know what? The data shows that OrthoATI is just as good as surgery for treating tennis elbow. That’s pretty cool, right?
Tennis elbow, or lateral epicondylitis, can be a real pain in the arm, literally. It affects loads of people every year and can really mess with your daily life. Usually, resting up, taking some anti-inflammatory meds, or doing some physio can sort it out within six months. But for some unlucky folks, those symptoms just won’t budge, even with steroid injections.
And that’s where OrthoATI comes in. For those with severe, chronic tennis elbow that won’t go away with the usual treatments, OrthoATI could be a game-changer. See, surgery is the last resort for these folks, and it’s not always a walk in the park. It’s invasive, expensive, and doesn’t always work. Plus, the rehab afterwards is no joke.
But now, with OrthoATI, there’s hope for a non-surgical fix. The Orthocell team is pretty stoked about these results, and they’re looking to make this treatment available worldwide. They’re also focusing on getting FDA approval for their nerve repair product, Remplir. Looks like they’re on a roll!
The study was led by some top-notch folks, including Clinical Professor Eugene Ek from Monash University, Dr Jason Harvey, Clinical Professor Allan Wang from the University of Western Australia, and Professor Ming Hao Zheng from the University of Western Australia (who’s also a co-founder of Orthocell).
Paul Anderson, the big boss at Orthocell, said, “These awesome clinical results just go to show how amazing the Orthocell team is and how much potential they have to help people all over the world. Oh, and by the way, we’ve got a US-based corporate adviser now to help us keep the ball rolling with our tendon cell therapy and focus on getting FDA approval for Remplir.”